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Background
In May 2009, a workshop was held in Washington, DC to
identify how HIV vaccine and Behavioral and Social Sci-
ence (BSS) researchers, along with relevant communities,
could undertake a more collaborative and integrative
approach to the area of HIV vaccine clinical research. The
workshop sought to identify challenges and opportunities
as well as break new ground operationally to advance
such an approach.
Methods
During the 1.5 day workshop, presentations on key BSS
topics, methodology and experiences were presented and
discussed. A community panel shared their experiences
and insights related to trial participation and community
engagement. To formulate concrete recommendations for
addressing specific BSS issues in upcoming HIV vaccine
clinical research, participants divided into groups to dis-
cuss the following topics: social impact, risk assessment,
community engagement, informed consent, risk reduc-
tion, and special populations.
Results
Seventy-one people from government and non-govern-
mental organizations participated, including HIV vaccine
researchers, clinical trialists, BSS researchers, community
representatives, and funders. Presentations, roundtables,
and a dedicated community panel each highlighted the
importance of ensuring BSSR is an integral component of
HIV vaccine clinical research throughout the research con-
tinuum. Issue-specific recommendations addressed the
need for: improved accuracy of data; standardization of
data collection to enable comparisons across studies;
community engagement at all levels; equipoise; evi-
denced-based counseling; dynamics of vulnerable, often
marginalized, populations; as well as consideration of
multiple complex influences. The importance of diffusing
these recommendations with change agents needed to
bring about this advance in research thinking and practice
was emphasized.
Conclusion
Improved consideration of BSS issues within a more inte-
grative research framework could improve the efficiency
and relevance of HIV vaccine clinical research. Efforts to
increase the integration and visibility of BSS aspects of this
research must continue.
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